Labetuzumab|cas:219649-07-7|西域试剂

Labetuzumab,95.00%

产品编号：Bellancom-P99160| CAS NO：219649-07-7

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99160	￥4200.00	杭州北京（现货）
Bellancom-P99160	￥8400.00	杭州北京（现货）
Bellancom-P99160	￥13500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Labetuzumab

产品介绍

Labetuzumab 是一种人源化抗癌胚抗原 (CEA) 单克隆抗体，可抑制肿瘤生长并使人类髓样甲状腺癌异种细胞对 Dacarbazine 化疗敏感。

生物活性

Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy.

体外研究

体内研究

Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nu/nu mice (6 to 8-week-old; inject TT cells).
Dosage:	0.5 mg/rat
Administration:	Intravenous injection; single (1 day post-tumor cell injection)
Result:	Significantly delaied growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60.

体内研究

Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nu/nu mice (6 to 8-week-old; inject TT cells).
Dosage:	0.5 mg/rat
Administration:	Intravenous injection; single (1 day post-tumor cell injection)
Result:	Significantly delaied growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60.